ObjectiveTo explore the clinical efficacy and safety of aspirin combined with clopidogrel dual antiplatelet, double loading dose sequential therapy in patients with transient ischemic attack (TIA). MethodsA total of 90 TIA patients admitted to the Department of Neurology in our hospital from January 2018 to March 2019 were selected and randomly divided into two groups. The observation group was administered aspirin combined with clopidogrel for dual antiplatelet, double loading dose sequential therapy. The control group was administered aspirin or clopidogrel monoclonal antibody with a conventional dose for treatment, for a six-month treatment course. The hemorheology indexes, clinical efficacy, the Short Form 36 Health Survey Questionnaire (SF-36), and adverse reactions were compared between the two groups. ResultsAfter 6 months of treatment, the levels of platelet aggregation, fibrinogen, high viscosity in whole blood, low viscosity in whole blood, and plasma viscosity of the two groups significantly decreased, and the levels mentioned above of the observation group were significantly lower than those of the control group, with statistically significant differences (P＜0.05). The total effective rate of treatment in the observation group was significantly higher than that in the control group, with a statistically significant difference (P＜0.05). The SF-36 scores of the two groups significantly increased, and the score of the observation group were significantly higher than that of the control group, with statistically significant difference (P＜0.05). During treatment, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05). ConclusionAspirin combined with clopidogrel dual antiplatelet, double loading dose sequential therapy in patients with transient ischemic attack can significantly improve hemorheology indicators, improve clinical therapeutic effects, improve life quality, but it does not increase adverse reactions.

无